Spero Therapeutics, Inc. (SPRO)

Market Cap	52.07M
Revenue (ttm)	106.46M
Net Income (ttm)	3.51M
Shares Out	54.52M
EPS (ttm)	0.06
PE Ratio	14.75
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	329,499
Open	0.990
Previous Close	0.998
Day's Range	0.950 - 0.990
52-Week Range	0.950 - 1.890
Beta	0.61
Analysts	Buy
Price Target	5.00 (+423.51%)
Earnings Date	Nov 14, 2024

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant e...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 2, 2017
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRO
• Website: https://sperotherapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for SPRO stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 423.51% from the latest price.

Price Target

$5.0

(423.51% upside)

Analyst Consensus: Buy